PDCD1 and neoplasm: Patients with resectable disease but a short disease-free interval (<6 months), unresectable satellite, ITMs or inoperable primary tumours of the limbs without additional metastases should be treated with systemic therapy, preferentially anti-programmed cell death protein 1 (PD-1)-based therapy, as these patients are at risk for developing distant metastasis.